Biocrates Enters Into Co-Marketing Agreement With Chenomx

The proprietary, patented technology platform of Biocrates is based on mass spectrometry. Chenomx analyzes biological samples utilizing a patented methodology based on Nuclear Magnetic Resonance (NMR) spectroscopy. Mass spectrometry offers high sensitivity and NMR offers a broad metabolite coverage.

Elgar Schnegg, CEO of Biocrates, said: “The research focus of both Biocrates and Chenomx is to identify and quantify endogenous metabolites in body fluid or tissue samples and develop them into powerful biomarkers.”

Neil Taylor, CEO of Chenomx, said: “The two methods produce complementary data sets with very little overlap in results. Both tests can be run on the same samples thus offering a more comprehensive profile.”

According to the companies, the study of the body’s small-molecule metabolites or ‘metabolomics’ in short, provides a snapshot of the physiologic state of an organism as determined by its genetic setup, regulation, protein abundance, and environmental influences. Rather than attempting to elucidate the effect a particular gene or protein may or may not have on the organism, metabolomics looks at the very endpoints of how diseases or drugs influence the human body.

With this partnership, both companies will now be able to offer complementary metabolomic analyses, service a common customer base, and jointly promote the use of each other’s services. Biocrates which boasts to be the only company in the field to have developed and brought to market a kit product for metabolomics, will also work in cooperation with Chenomx in evaluating and optimizing the performance of its kit products on its partner’s instrumentation and software.

The companies believe that the collaborative research efforts between them will consequently enable diseases to be detected early, assess disease severity more accurately, encourage the development of targeted medicines, monitor therapy more efficiently and tailor treatment to the individual needs of a patient.